Walidacja skali BASED jako predyktora opornej epilepsji po leczeniu zespołu infantylnych spazmatycznych napadów padaczkowych
PubMed➕ 18.11.2026Neurology
Validation of the BASED Score as a Prognostic Biomarker for Refractory Epilepsy Following Treatment of Infantile Epileptic Spasms Syndrome
W skrócie
Badanie sprawdziło, czy specjalny wynik w badaniu EEG (skala BASED 4/5) wykonanym po leczeniu infantylnych spazmatycznych napadów padaczkowych może przewidywać, które dzieci będą miały oporną epilepsję trudną do kontrolowania lekami. U ponad połowy badanych dzieci rozwinęła się oporna epilepsja, a wynik BASED 4/5 okazał się dobrym wskaźnikiem tego zagrożenia z dokładnością 88%. Wyniki sugerują, że ta skala może pomóc lekarzom w wczesnym zidentyfikowaniu dzieci, które będą wymagać intensywniejszego leczenia.
Oryginalny abstract (angielski)
BACKGROUND AND OBJECTIVES: Refractory epilepsy is common among children with a history of infantile epileptic spasms syndrome (IESS), yet no validated prognostic biomarkers exist to guide early risk stratification. The Burden of Amplitudes and Epileptiform Discharges (BASED) score is an interictal EEG rating scale for children with IESS, with scores of 4 or 5 suggesting epileptic encephalopathy. The objective of this study was to determine whether a post-treatment BASED score of 4/5 is a prognostic biomarker for refractory epilepsy after IESS treatment. METHODS: This retrospective validation study of children with IESS was conducted at a Level 4 pediatric epilepsy center. Children with tuberous sclerosis complex (TSC) were excluded. Three blinded reviewers assigned 2021 BASED scores to full-length post-treatment EEGs. Refractory epilepsy was defined as persistent seizures despite treatment with at least 2 antiseizure medications or completion of epilepsy surgery. Prespecified performance benchmarks for BASED 4/5 as a rule-in test required ≥80% specificity and a positive likelihood ratio of ≥4. RESULTS: The cohort included 123 children (42.3% female), with a median first treatment age of 8.0 months (IQR 5.9-10.3) and follow-up duration after first treatment of 58.8 months (IQR 42.2-80.7). Only 11.4% had a favorable etiology. EEGs (median 19 hours) were completed at a median of 47 days (32-72) after starting treatment. The inter-rater agreement for epileptic encephalopathy was excellent (κ = 0.78). Half (52%) of the children had refractory epilepsy. BASED 4/5 demonstrated high specificity (88.1%, 95% CI 77.1-95.1) for refractory epilepsy, with a positive likelihood ratio of 4.4 (2.1-9.1). The sensitivity, positive predictive value, and negative predictive value were 51.6% (38.7-64.3), 82.5% (69.3-90.8), and 62.7% (56.1-68.7), respectively. An exploratory composite indicator comprising BASED 4/5, persistent epileptic spasms, and/or epileptic spasms relapse demonstrated higher sensitivity (79.7%, 67.8-88.7) with modestly reduced specificity (81.4%, 69.1-90.3). DISCUSSION: Study limitations include the single-center design, exclusion of children with TSC, variable EEG timing, and shorter follow-up in some children. Nevertheless, in this independent validation cohort, a post-treatment BASED 4/5 demonstrated favorable prognostic performance consistent with its proposed use as a rule-in test for refractory epilepsy. These findings support a post-treatment BASED score of 4/5 as a prognostic biomarker for refractory epilepsy after IESS treatment.
Metadane publikacji
Journal
Neurology
Data publikacji
22.12.2026
PMID
43044079
DOI
10.1212/WNL.0000000000218751
Autorzy
Mytinger JR, Lo WD, Weber AB, Vidaurre J, Patel AD, McCabe C, Fredwall MM, Choudhari PR, Beatty CW, Aylward S